Iain McInnes, PhD, FRCP
Professor of Medicine and Rheumatology
University of Glasgow
Glasgow, United Kingdom
Disclosure information not submitted.
Joseph Merola, MD, MSc
Associate Professor, Dept Dermatology and Dept of Medicine, Division of Rheumatology at Harvard Medical School
Harvard Medical School, Brigham and Women's Hospital
Newton, MA, United States
Disclosure(s): Abbvie: Consultant (Ongoing); Amgen: Consultant (Ongoing); Biogen: Consultant (Ongoing), Grant/Research Support (Ongoing); Bristol-Myers Squibb(BMS): Consultant (Ongoing); Dermavant: Consultant (Ongoing); Eli Lilly: Consultant (Ongoing); Inctye: Grant/Research Support (Ongoing); Janssen: Consultant (Ongoing); Novartis: Consultant (Ongoing), Grant/Research Support (Ongoing); Pfizer: Consultant (Ongoing), Grant/Research Support (Ongoing); Sanofi: Consultant (Ongoing), Grant/Research Support (Ongoing); Sun Pharma: Consultant (Ongoing); UCB: Consultant (Ongoing)
Lianne Gensler, MD
Professor of Medicine
University of California San Francisco
San Francisco, CA, United States
Disclosure(s): AbbVie/Abbott: Consultant (Ongoing); Eli Lilly: Advisor or Review Panel Member (Ongoing), Consultant (Ongoing); Gilead: Advisor or Review Panel Member (Terminated); Janssen: Advisor or Review Panel Member (Terminated); Novartis: Advisor or Review Panel Member (Ongoing), Consultant (Ongoing), Grant/Research Support (Ongoing); Pfizer: Advisor or Review Panel Member (Terminated), Consultant (Terminated), Grant/Research Support (Terminated); UCB: Advisor or Review Panel Member (Ongoing), Consultant (Ongoing)
If left uncontrolled, inflammatory joint diseases can cause progressive structural joint damage and irreversible disability. Early identification and treatment initiation is crucial for successful outcomes in patients with inflammatory joint disease. In this symposium expert faculty will discuss the rationale for long-term disease control and how to improve standards of care based on shared decision making, patient characteristics and preferences. Recommendations on how to select treatments will be discussed in light of the latest clinical evidence.
Medscape, LLC designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Developed and offered by Medscape, LLC and supported by UCB Pharma Global
